2月25日，丰倍生物跌3.55%，成交额1.74亿元。两融数据显示，当日丰倍生物获融资买入额1721.77万 元，融资偿还3269.51万元，融资净买入-1547.74万元。截至2月25日，丰倍生物融资融券余额合计 7981.37万元。 融资方面，丰倍生物当日融资买入1721.77万元。当前融资余额7981.37万元，占流通市值的4.77%。 融券方面，丰倍生物2月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 资料显示，苏州丰倍生物科技股份有限公司位于江苏省常州市金坛区兴河东路19号，成立日期2014年7 月25日，上市日期2025年11月5日，公司主营业务涉及以废弃油脂资源综合利用业务为主,油脂化学品业 务为辅。主营业务收入构成为：废弃资源综合利用业务91.18%，其中:生物基材料79.60%，其中:生物燃 料11.58%，油脂化学品8.66%，其他(补充)0.16%。 截至12月10日，丰倍生物股东户数2.76万，较上期减少50.19%；人均流通股1123股，较上期增加 100.77%。2025年1月-9月，丰倍生物实现营业 ...

Group 1 - The core viewpoint of the news is that Fengbei Bio experienced a decline in stock price and trading volume, with significant net financing outflows on February 12, indicating potential investor concerns [1] - On February 12, Fengbei Bio's stock price fell by 3.03%, with a trading volume of 199 million yuan. The net financing buy was -6.46 million yuan, with a total financing balance of 97.52 million yuan, accounting for 5.87% of the circulating market value [1] - The company specializes in the comprehensive utilization of waste oil resources, with its main business revenue composition being 91.18% from waste resource utilization, including 79.60% from bio-based materials and 11.58% from biofuels [1] Group 2 - As of December 10, the number of shareholders for Fengbei Bio was 27,600, a decrease of 50.19% from the previous period, while the average circulating shares per person increased by 100.77% [2] - For the period from January to September 2025, Fengbei Bio achieved an operating income of 2.251 billion yuan, representing a year-on-year growth of 62.32%, and a net profit attributable to the parent company of 117 million yuan, up 35.32% year-on-year [2]

Market Performance - Zanyu Technology (002637) experienced a volatile stock price movement from February 6 to February 11, 2026, with a cumulative increase of 1.75% and a fluctuation range of 8.15% [1] - On February 6, the stock price rose by 3.42% to 14.22 CNY, with a trading volume of 198 million CNY; on February 9, it fell by 3.73% to 13.69 CNY; and on February 11, it increased by 3.17% to 13.99 CNY, with a trading volume of 173 million CNY [1] - The net inflow of main funds was 6.0086 million CNY, indicating a recent trend of net inflow from institutional investors [1] Financial Performance - For the period from January to September 2025, Zanyu Technology reported an operating revenue of 9.676 billion CNY, representing a year-on-year growth of 27.92% [2] - The net profit attributable to the parent company was 151 million CNY, reflecting a year-on-year increase of 24.96% [2] - The main business segments include oil chemical products, accounting for 52.21%, and surfactants, accounting for 45.59%, with growth driven by increased demand for chemical products [2] Dividend Policy - Since its listing, the company has distributed a total of 637 million CNY in dividends, with 149 million CNY distributed over the past three years, demonstrating stable profitability [2]

Group 1 - The core point of the news is that Fengbei Biotechnology's stock has experienced a decline of 2.54%, with a total market value of 7.937 billion yuan and a cumulative drop of 6.73% over three consecutive days [1] - Fengbei Biotechnology, established on July 25, 2014, focuses on the comprehensive utilization of waste oil resources, with 91.18% of its revenue coming from this segment, including 79.60% from bio-based materials and 11.58% from biofuels [1] - The company's stock price is currently at 55.31 yuan per share, with a trading volume of 189 million yuan and a turnover rate of 10.80% [1] Group 2 - E Fund's fund holds a small position in Fengbei Biotechnology, with 88 shares representing 0.0002% of the circulating shares, ranking as the fourth largest holding [2] - The fund has incurred a floating loss of approximately 126.72 yuan today and a total floating loss of 351.12 yuan during the three-day decline [2] - E Fund's fund has a total asset size of 5.93 billion yuan, with a year-to-date return of 15.3% and a cumulative return of 20.92% since inception [2]

会议演讲/路演报名（审核制） 请添加下方微信 声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由仅作新材料相关领域介绍，本文不构成任何投资 建议！转载请注明来源！ 近日， 丰倍生物 （ 603334）接受投资者调研时表示，其生产的 生物柴油 主要用于对外销售和进一步 复配成生物柴油配方产品 ，同时2024年起随着公司对上游原料端的持续布局， 加大了工业级混合油对 外销售规模 。 公司2025年1-6月公司 生物柴油 产量为 47,706.75吨， 工业级混合油 产量为142,814.10 吨 。 据悉， 丰倍生物成立于2014年，是一家废弃资源综合利用领域的高新技术企业，主要以废弃油脂生产 资源化产品 。基于长期的研发投入和产业实践，公司在废弃油脂资源综合利用的深度及广度上不断拓 展，形成了 "废弃油脂—生物燃料（生物柴油）—生物基材料" 的废弃资源再生产业链。此外，公司还 依托自身油脂综合利用核心技术和渠道优势为客户提供油脂化学品。 其废弃油脂 主要来源于粮油食品加工企业、油脂化工企业、餐厨处理企业 等。公司在全国范围内多点 布局知名粮油食品加工企业、油脂化工企业、餐厨处理企业、 区 ...

Group 1 - The core viewpoint of the news is that Fengbei Bio has shown a mixed performance in terms of financing activities and stockholder statistics, with a notable increase in revenue and profit year-on-year [1][2] Group 2 - On January 19, Fengbei Bio's stock price increased by 0.54%, with a trading volume of 213 million yuan. The financing buy-in amount for the day was 11.46 million yuan, while the financing repayment was 12.08 million yuan, resulting in a net financing buy of -0.62 million yuan [1] - As of January 19, the total balance of margin trading for Fengbei Bio was 83.27 million yuan, accounting for 5.15% of its circulating market value [1] - The company has not engaged in any short selling activities on January 19, with no shares sold or repaid [1] Group 3 - As of December 10, the number of shareholders for Fengbei Bio was 27,600, a decrease of 50.19% compared to the previous period, while the average circulating shares per person increased by 100.77% to 1,123 shares [2] - For the period from January to September 2025, Fengbei Bio achieved an operating income of 2.251 billion yuan, representing a year-on-year growth of 62.32%, and a net profit attributable to shareholders of 117 million yuan, which is a 35.32% increase year-on-year [2] Group 4 - Fengbei Bio, established on July 25, 2014, is located in Changzhou, Jiangsu Province, and primarily focuses on the comprehensive utilization of waste oil resources, with oil chemical products as a secondary business [1] - The main business revenue composition includes 91.18% from waste resource utilization, with 79.60% from bio-based materials, 11.58% from biofuels, and 8.66% from oil chemical products [1]

Group 1 - The core viewpoint of the news is that Fengbei Bio has experienced fluctuations in its stock performance and financing activities, with a notable decrease in net financing buy on December 18 [1] - On December 18, Fengbei Bio's stock price fell by 0.40%, with a trading volume of 47.94 million yuan, and a net financing buy of -1.63 million yuan [1] - As of December 18, the total balance of margin trading for Fengbei Bio was 95.01 million yuan, accounting for 7.28% of its market capitalization [1] Group 2 - As of December 10, the number of shareholders for Fengbei Bio was 27,600, a decrease of 50.19% compared to the previous period [2] - The average number of circulating shares per shareholder increased by 100.77% to 1,123 shares [2] - For the period from January to September 2025, Fengbei Bio achieved operating revenue of 2.251 billion yuan, representing a year-on-year growth of 62.32%, and a net profit attributable to shareholders of 117 million yuan, up 35.32% year-on-year [2]

Core Viewpoint - The company, Fengbei Bio, is a high-tech enterprise in the field of waste resource utilization, primarily focusing on the production of resource-based products from waste oils [1] Group 1: Company Overview - Fengbei Bio has made long-term investments in research and development, continuously expanding the depth and breadth of waste oil resource utilization [1] - The company has established a waste resource recycling industry chain that includes "waste oil - biofuels (biodiesel) - bio-based materials" [1] - The company leverages its core technology in oil fat utilization and channel advantages to provide chemical products derived from oils to its customers [1]

Group 1 - The core point of the article is that Fengbei Bio announced a board meeting to discuss changes in registered capital, company type, and amendments to the articles of association, along with the need for business registration changes [1] - For the first half of 2025, Fengbei Bio's revenue composition is as follows: bio-based materials accounted for 79.6%, biofuels for 11.58%, oleochemical products for 8.66%, and other businesses for 0.16% [1] - As of the report date, Fengbei Bio has a market capitalization of 6.3 billion yuan [1]

Group 1: Company Overview - Zanyu Technology Group is a high-tech enterprise specializing in the research and manufacturing of surfactants, fatty chemical products, and personal care products (OEM/ODM processing) [2] - The company has become a leading enterprise in the domestic research and production of surfactants and fatty chemical products [2] - The headquarters is located in Hangzhou, with production bases in multiple locations including Zhejiang, Jiangsu, Sichuan, Henan, Guangdong, and Indonesia [2] Group 2: Production Capacity - Annual production capacity for surfactants exceeds 1.2 million tons [2] - Annual production capacity for fatty chemical products exceeds 1 million tons [2] - OEM/ODM processing capacity for personal care products reaches 1.1 million tons [2] Group 3: Product Applications - Surfactants are primarily used in detergents, cosmetics, food processing, and textile dyeing industries [3] - Fatty chemical products are applied in plastics, rubber, textiles, daily chemicals, leather, paper, and oil fields, indicating a broad market potential [3] Group 4: Export Markets - The company's export business targets countries and regions along the "Belt and Road," RCEP, the African Free Trade Area, and Latin America [3] Group 5: Raw Material and Cost Management - Key raw materials include palm oil, C12-14 alcohol, alkylbenzene, and olefins, with price fluctuations impacting production costs [4] - The company has implemented a pricing model adjustment and commodity hedging to mitigate the impact of raw material price volatility on performance [4] Group 6: Future Strategy - The company aims to enhance its market share and competitiveness by focusing on surfactants, fatty chemical products, and personal care products, while leveraging technological innovation and supply chain management [4] - The goal is to become a globally outstanding chemical manufacturing service provider [4]